Business Wire

Blue Earth Diagnostics Announces Results of Additional Analyses from LOCATE Trial Evaluating Change in Recurrent Prostate Cancer Management Following Axumin ® (Fluciclovine F ...

The LOCATE trial was a prospective, U.S., multicenter, open-label study investigating the impact of 18 F-fluciclovine PET/CT imaging on patient management of biochemically recurrent prostate cancer ...
EurekAlert!

Imaging tool helps locate recurrent prostate cancer

DURHAM, N.C. -- A new multi-institutional study led by investigators at Duke University Medical Center indicates that a diagnostic scan may help localize recurrent prostate disease in men who have had ...
EurekAlert!

UCLA researchers locate and image prostate cancer as it spreads to lymph nodes

Using an engineered common cold virus, UCLA researchers delivered a genetic payload to prostate cancer cells that allowed them, using Positron Emission Tomography (PET), to locate the diseased cells ...
Business Wire

Blue Earth Diagnostics Announces Axumin® (Fluciclovine F 18) LOCATE Study Presentation at Upcoming ASCO 2019 Genitourinary Cancers Symposium on Impact on Clinical Management ...

BURLINGTON, Mass. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced the upcoming presentation of additional analyses from the LOCATE ...
CNN

SonaCare Medical and Invivo Join Forces to Help Physicians Better Locate and Track Appropriate Targets for Prostate HIFU Ablation

CHARLOTTE, N.C., May 5, 2016 /PRNewswire/ -- SonaCare Medical, the leading developer and manufacturer of High Intensity Focused Ultrasound (HIFU) Technologies, announces today a marketing alliance ...